When was Finch Therapeutics founded?

Finch Therapeutics was founded in 2004 and raised its 1st funding round 11 years after it was founded.

Where is Finch Therapeutics located?

Finch Therapeutics is headquartered in Somerville, United States.

How many employees does Finch Therapeutics have?

As of Sep 30, 2026, the latest employee count at Finch Therapeutics is 13.

Is Finch Therapeutics a funded company?

Finch Therapeutics is a funded company, having raised a total of $184M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 29, 2015.

When was the latest funding round of Finch Therapeutics?

Finch Therapeutics' latest funding was a $***** Series D round on Sep 17, 2020, with participation from 13 investors.

What is the annual revenue of Finch Therapeutics?

Annual revenue of Finch Therapeutics is less than $1M as on Dec 31, 2023

Where does Finch Therapeutics rank among its competitors?

Finch Therapeutics ranks 357th amongst 3064 active competitors, of which 1053 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Finch Therapeutics?

Finch Therapeutics' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Finch Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Finch Therapeutics is a developer of microbiome-based therapies using a human-first discovery platform. It is using proprietary machine learning techniques to build a clinically annotated library of strains that drive clinical phenotypes of interest. It has also developed an AquaShell for targeted delivery of microbial therapeutics. Its products mainly focussed on Inflammatory Bowel Disease (preclinical), and others.

Website: www.finchtherapeutics.com/
Social
Email ID: *****@finchtherapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2004

Location

Somerville, United States

Stage

Public

Total Funding

$184M in 5 rounds

Latest Funding Round

Series D, Sep 17, 2020, $*****

Investors

Shumway Capital & 20 more

Ranked

357^th among 3064 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2023

Employee Count

13 as on Sep 30, 2026

Similar Companies

Alnylam & 908 more

Exit Details

Public

View Finch Therapeutics' full profile

Finch Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
FINCH THERAPEUTICS GROUP, INC. CIN: 1733257 , United States, Active	Sep 20, 2017	$0 - $1M (As on Dec 31, 2023)	-	-
Finch Therapeutics Group, Inc CIN: 6547340 , United States, Active	Sep 20, 2017	-	189 (As on Dec 31, 2021)	-

Finch Therapeutics got listed on Mar 19, 2021.

Click here to take a look at Finch Therapeutics's IPO in detail

Finch Therapeutics has raised a total funding of $184M over 5 rounds. Its first funding round was on Dec 29, 2015. Its latest funding round was a Series D round on Sep 17, 2020 for $*****. 13 investors participated in its latest round. Finch Therapeutics has 21 institutional investors.

Here is the list of recent funding rounds of Finch Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 2020	7676019	Series D	9587797	7370724	7844444	5877753
Jul 19, 2019	7979694	Series C	5276683	4871267	4718209	OCV Partners & 7 more
Mar 01, 2018	3241860	Series B	2972065	6902294	Shumway Capital & 3 more	2303164

Access funding benchmarks and valuations. Sign up today!

View details of Finch Therapeutics's funding rounds and investors

The founders of Finch Therapeutics are Jared James Burgess, Tom Borody and Zain Kassam.

Here are the details of Finch Therapeutics' key team members:

Jared James Burgess: Co-Founder of Finch Therapeutics and founder of 1 other company. They serve on the board of 1 company.
Tom Borody: Co-Founder of Finch Therapeutics.
Zain Kassam: Co-Founder of Finch Therapeutics.

View details of Finch Therapeutics's Founder profiles and Board Members

Finch Therapeutics' employee count trend

Finch Therapeutics has 13 employees as of Sep 26. Here is Finch Therapeutics's employee count trend over the years:

Employee count trend for Finch Therapeutics

Uncover Finch Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Finch Therapeutics include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Finch Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
357th	Finch Therapeutics 2004, Somerville (United States), Public	Developer of microbiome-based therapies by using human-first discovery platform	$184M	The Baupost Group, SymBiosis & 19 others	55/100